NTP42 是血栓素 A2 (TXA2) 受体的拮抗剂，IC50为 3.278 nM，可用于肺动脉高压的相关研究。

NTP42 is an antagonist of thromboxane A2 (TXA2) receptor(IC50 of 3.278 nM)

From haemodynamic assessments, NTP42 reduced the MCT-induced PAH, including mean pulmonary arterial pressure (mPAP) and right systolic ventricular pressure (RSVP), being at least comparable to the standard-of-care drugs Sildenafil or Selexipag in bringing about these effects.?Moreover, NTP42 was superior to Sildenafil and Selexipag in significantly reducing pulmonary vascular remodelling, inflammatory mast cell infiltration and fibrosis in MCT-treated animals[1].

2055599-51-2

C25H23F2N3O5S

515.53

DMSO:30mg/mL (58.19 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years